Product Name: Abiraterone CAS NO: 154229-19-3
Chemical & Physical Properties:
Appearance :white powder
Boiling Point:500.2℃ at 760 mmHg
Abiraterone is a targeted cytochrome CYP17 (17α-hydroxylase/C17,20-lyase) inhibitor, which produces abiraterone after hydrolysis. Abiraterone acetate reduces the production of testosterone by inhibiting cytochrome CYP17 It is suitable for the treatment of patients with metastatic and refractory prostate cancer (CRPC) who have received chemotherapy containing docetaxel. Clinical trials have shown that abiraterone combined with prednisone can significantly prolong the overall survival of patients with metastatic prostate cancer who have previously received docetaxel chemotherapy. A follow-up study found that abiraterone also has a significant effect on patients who did not receive docetaxel chemotherapy. According to this, abiraterone is listed as the first-line treatment for metastatic CRPC in the guidelines. The latest research shows that abiraterone can benefit patients with locally advanced or metastatic prostate cancer. These results will promote abiraterone into the first-line treatment of advanced prostate cancer early.
If you are interested in our products or have any questions, please feel free to contact us!
Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.